Related coverage linked through entity extraction aliases.
Feb 17, 2026
Compass Pathways reported positive phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant symptom reduction. The company plans to discuss FDA filing with a New Drug Application expected in Q4 2026.
Feb 17, 2026
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
Feb 16, 2026
The American Psychiatric Association released a roadmap for the future DSM in January 2026, proposing to incorporate biomarkers and rename the manual to reflect scientific scope. A new conceptual framework suggests using electrical and chemical signals to explain mental disorders and human intelligence.
Feb 14, 2026
A population-based study of over 1.27 million births found SSRI antidepressants during pregnancy increase gestational diabetes risk but reduce preterm birth and low birth weight risks, with effects independent of maternal depression.
Feb 13, 2026
Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.
Feb 10, 2026
New research shows wearable devices can predict depression relapses weeks in advance through sleep pattern analysis, while studies reveal limitations in Apple Watch blood pressure alerts and benefits of replacing TV time with physical activity.
Feb 10, 2026
The Trump administration launched TrumpRx.gov in February 2026, offering discounted prices on dozens of brand-name prescription drugs through negotiated deals with pharmaceutical companies, though critics warn many listed drugs have cheaper generic alternatives.
